Ironwood Pharmaceuticals Stock Analysis
IRWD Stock | USD 7.92 0.32 4.21% |
Ironwood Pharmaceuticals is undervalued with Real Value of 9.75 and Target Price of 16.5. The main objective of Ironwood Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Ironwood Pharmaceuticals is worth, separate from its market price. There are two main types of Ironwood Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Ironwood Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Ironwood Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Ironwood Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Ironwood Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Ironwood Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Ironwood Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Ironwood |
Ironwood Stock Analysis Notes
About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 6.45. Ironwood Pharmaceuticals last dividend was issued on the 2nd of April 1970. The entity had 1194:1000 split on the 2nd of April 2019. Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Ironwood Pharmaceuti operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 219 people. To learn more about Ironwood Pharmaceuticals call Mark Mallon at 617 621 7722 or check out https://www.ironwoodpharma.com.Ironwood Pharmaceuticals Quarterly Total Revenue |
|
Ironwood Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ironwood Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ironwood Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ironwood Pharmaceuticals generated a negative expected return over the last 90 days | |
Ironwood Pharmaceuticals has high historical volatility and very poor performance | |
Ironwood Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 442.74 M. Net Loss for the year was (1 B) with profit before overhead, payroll, taxes, and interest of 366.33 M. | |
Over 98.0% of the company shares are owned by institutional investors | |
Latest headline from investing.com: Jaguar Health names new SVP of Growth Strategy |
Ironwood Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Ironwood Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ironwood Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
15th of February 2024 Upcoming Quarterly Report | View | |
2nd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
15th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Ironwood Largest EPS Surprises
Earnings surprises can significantly impact Ironwood Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2020-05-06 | 2020-03-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2011-05-12 | 2011-03-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2011-03-03 | 2010-12-31 | -0.14 | -0.12 | 0.02 | 14 |
Ironwood Pharmaceuticals Thematic Classifications
In addition to having Ironwood Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Obamacare RepealLarge healthcare related equities associated with Obamacare |
Ironwood Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ironwood Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ironwood Pharmaceuticals backward and forwards among themselves. Ironwood Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Ironwood Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Geode Capital Management, Llc | 2023-12-31 | 3.1 M | Jacobs Levy Equity Management, Inc. | 2023-09-30 | 2.4 M | Jupiter Asset Management Limited | 2023-12-31 | 2.3 M | Goldman Sachs Group Inc | 2023-12-31 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 2.1 M | Nuveen Asset Management, Llc | 2023-12-31 | 1.8 M | Northern Trust Corp | 2023-12-31 | 1.6 M | Driehaus Capital Management Llc | 2023-12-31 | 1.6 M | Adage Capital Partners Gp Llc | 2023-12-31 | 1.5 M | Blackrock Inc | 2023-12-31 | 26 M | Sarissa Capital Management Lp | 2023-09-30 | 16.4 M |
Ironwood Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.24 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ironwood Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Ironwood Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Ironwood Profitablity
Ironwood Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Ironwood Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Ironwood Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ironwood Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ironwood Pharmaceuticals' profitability requires more research than a typical breakdown of Ironwood Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.26) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.03 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.03. Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (2.14) | (2.04) | |
Return On Capital Employed | 1.07 | 1.13 | |
Return On Assets | (2.13) | (2.02) | |
Return On Equity | 2.89 | 3.04 |
Management Efficiency
Ironwood Pharmaceuticals has return on total asset (ROA) of 0.1339 % which means that it generated a profit of $0.1339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.7404) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | (2.23) | (2.34) | |
Net Current Asset Value | 0.00 | 0.00 | |
Tangible Asset Value | 0.00 | 0.00 | |
Tangible Book Value Per Share | (2.25) | (2.36) | |
Enterprise Value Over EBITDA | 11.40 | 11.97 | |
Price Book Value Ratio | (5.13) | (4.88) | |
Enterprise Value Multiple | 11.40 | 11.97 | |
Price Fair Value | (5.13) | (4.88) | |
Enterprise Value | 2.2 B | 2.4 B |
The analysis of Ironwood Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Ironwood Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Ironwood Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.549 |
Technical Drivers
As of the 19th of April, Ironwood Pharmaceuticals retains the Risk Adjusted Performance of (0.05), market risk adjusted performance of (3.85), and Standard Deviation of 5.26. Ironwood Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We are able to interpolate and break down thirteen technical drivers for Ironwood Pharmaceuticals, which can be compared to its competitors. Please check out Ironwood Pharmaceuticals information ratio and skewness to decide if Ironwood Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 7.92 per share. Given that Ironwood Pharmaceuticals has information ratio of (0.10), we strongly advise you to confirm Ironwood Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.Ironwood Pharmaceuticals Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ironwood Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ironwood Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Ironwood Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ironwood Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ironwood Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ironwood Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sravan Emany 18 hours ago Disposition of 41332 shares by Sravan Emany of Ironwood Pharmaceuticals at 14.9 subject to Rule 16b-3 | ||
Denner Alexander J over a month ago Acquisition by Denner Alexander J of 1662 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | ||
Vr Management Llc over six months ago Acquisition by Vr Management Llc of 181 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 |
Ironwood Pharmaceuticals Outstanding Bonds
Ironwood Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ironwood Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ironwood bonds can be classified according to their maturity, which is the date when Ironwood Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
US46333XAF50 Corp BondUS46333XAF50 | View | |
US46333XAH17 Corp BondUS46333XAH17 | View |
Ironwood Pharmaceuticals Predictive Daily Indicators
Ironwood Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ironwood Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 124413.0 | |||
Daily Balance Of Power | 0.8205 | |||
Rate Of Daily Change | 1.04 | |||
Day Median Price | 7.75 | |||
Day Typical Price | 7.8 | |||
Price Action Indicator | 0.34 | |||
Period Momentum Indicator | 0.32 |
Ironwood Pharmaceuticals Corporate Filings
F4 | 19th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 12th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 8th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 7th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 6th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 16th of February 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 15th of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 14th of February 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Ironwood Pharmaceuticals Forecast Models
Ironwood Pharmaceuticals' time-series forecasting models are one of many Ironwood Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ironwood Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Ironwood Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Ironwood Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ironwood shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ironwood Pharmaceuticals. By using and applying Ironwood Stock analysis, traders can create a robust methodology for identifying Ironwood entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (2.14) | (2.25) | |
Operating Profit Margin | 0.47 | 0.50 | |
Net Loss | (2.26) | (2.38) | |
Gross Profit Margin | 1.00 | 0.74 |
Current Ironwood Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ironwood analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ironwood analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
16.5 | Strong Buy | 6 | Odds |
Most Ironwood analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ironwood stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ironwood Pharmaceuticals, talking to its executives and customers, or listening to Ironwood conference calls.
Ironwood Stock Analysis Indicators
Ironwood Pharmaceuticals stock analysis indicators help investors evaluate how Ironwood Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ironwood Pharmaceuticals shares will generate the highest return on investment. By understating and applying Ironwood Pharmaceuticals stock analysis, traders can identify Ironwood Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 657.5 M | |
Long Term Debt | 498.3 M | |
Common Stock Shares Outstanding | 155.4 M | |
Total Stockholder Equity | -346.3 M | |
Tax Provision | 74.8 M | |
Quarterly Earnings Growth Y O Y | -0.685 | |
Property Plant And Equipment Net | 18.2 M | |
Cash And Short Term Investments | 92.2 M | |
Cash | 92.2 M | |
Accounts Payable | 7.8 M | |
Net Debt | 623.4 M | |
50 Day M A | 10.771 | |
Total Current Liabilities | 276.1 M | |
Other Operating Expenses | 233.7 M | |
Non Current Assets Total | 237.8 M | |
Forward Price Earnings | 12.3305 | |
Non Currrent Assets Other | 3.6 M | |
Stock Based Compensation | 32 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Transaction History View history of all your transactions and understand their impact on performance | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.69) | Earnings Share (6.45) | Revenue Per Share 2.848 | Quarterly Revenue Growth 0.097 | Return On Assets 0.1339 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.